TITLE

New melanoma drug requires gene mutation test

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
October 2011
SOURCE
American Journal of Health-System Pharmacy;10/1/2011, Vol. 68 Issue 19, p1764
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports the FDA approval of vemurafenib, marketed as Zelboraf by Roche Group's Genentech, for use against melanoma having a V600E genetic mutation in the gene that encodes the protein kinase BRAF. The article mentions that a study shows that vemurafenib helps improve overall survival in patients, with a risk of cutaneous squamous cell carcinoma in 26 percent of treated patients. It is mentioned that the drug is available only through specialty pharmacies.
ACCESSION #
65580784

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics